News

The company said it will stop trial based on significant positive results from interim analysis. According to the company, the MN-001 significantly reduced mean serum triglycerides, which is a

Redx said it communicated with the Medicines and Healthcare products Regulatory Agency (MHRA) to interrupt the clinical trial of the Porcupine inhibitor. The company detected significant adverse events

Under this collaboration, Actinium will utilize its AWE Platform to conjugate and label selected Astellas targeting agents with the powerful actinium-225 (225Ac) payload. Actinium will also be responsible

bluebird bio corporate development and strategy oncology franchise leader and senior vice president Joanne Smith-Farrell said: "Entering into this co-development and co-promotion partnership with Celgene is a significant

Takeda announced that its consideration of such an offer is at a preliminary and exploratory stage and no approach has been made to the board of Shire. Shire

Daiichi Sankyo R&D Division Oncology Function head, executive officer Koichi Akahane said: "There are no HER2-targeting treatment options currently available for patients with HER2-positive gastric cancer whose tumors

This decision followed a planned interim analysis by an independent Data Monitoring Committee (DMC) of unblinded efficacy and safety data from the first 65 patients from the ongoing

Pedmark, a formulation of sodium thiosulfate (STS), is a water-soluble thiol compound that serves as a chemical reducing agent. Delayed administration (between four to eight hours) of high dose

In 2015, the consumer healthcare JV was established, as part of a three-part inter-conditional transaction between GSK and Novartis. The JV is a combination of Novartis' over-the-counter (OTC)